Persistence Market Research
Regenerative Therapies for Osteoarthritis Market- Snapshot
Osteoarthritis is a condition that is described as a degenerative joint disorder. The disease is considered as one of the leading cause of disability among geriatric population. The main cause of the disease is deprived lack of specific diagnostic biomarkers and self-healing capacity.
Regenerative therapies for osteoarthritis is revolutionizing the treatment area by repairing the damaged tissue or organs by replacing patient’s own regenerated tissues. This helps in initiating the natural healing process. The effectiveness of the therapies for the treatment of osteoarthritis is the primary reason behind the unprecedented adoption of the regenerative.
Further, the researchers are focusing towards the development of advanced regenerative therapies for effective for osteoarthritis such as monoclonal antibody against ?-nerve growth and recombinant human fibroblast growth factor-18.
Some of the factor expected to drive the growth of the global regenerative therapies for osteoarthritis market is significant rise in geriatric population with orthopaedic disease across the globe. As per a study, geriatric pollution is expected to rise by 30 percent by 2030. Also, the number of population affected with osteoarthritis is expected to increase due to growing obese population across the globe.
Osteoarthritis is a degenerative joint disorder and one of the leading cause of disability in geriatric population. Osteoarthritis is a challenging disease due to the deprived self-healing capacity and lack of specific diagnostic biomarkers. There are limited treatment options available for the osteoarthritis which includes pain killer and anti-inflammatory medications, however no medications are available to heal the cartilage damage in the osteoarthritis patients. Regenerative medicine is a revolutionized area of medicine in which damaged tissue or organs are replaced with the patient’s own regenerated tissues in order to initiate natural healing process. Thus, many of the researchers are focusing on the development of regenerative medication effective for osteoarthritis such as monoclonal antibody against ?-nerve growth factor and recombinant human fibroblast growth factor-18.
The prime growth driver for the global regenerative therapies for osteoarthritis market is increasing population with orthopedic disease and poor availability of effective medication for osteoarthritis. In North America, ~10% of men and 13% of women aged above 60 years are suffering from osteoarthritis. Also, the number of population affected with osteoarthritis is expected to increase due to growing obese population across the globe. In addition, government support for treatment of orthopedic diseases is increasing owing to the implementation of supportive legislative and policy initiatives. Furthermore, increasing demand for stem cell and tissue based research technologies and their products are also driving the growth for the global regenerative therapies for osteoarthritis market currently. However, availability of low cost alternatives such as open surgeries and synthetic drugs are few of the factors hampering the regenerative therapies for osteoarthritis market growth to some extent.
Regenerative Therapy for Osteoarthritis Market Segmentation by Therapy Type
Regenerative Therapy for Osteoarthritis Market Segmentation by End User
Product type regenerative therapy for osteoarthritis segment includes cell therapy, tissue engineering Regenerative Therapy for Osteoarthritis and gene therapy, among which, cell based regenerative therapy for osteoarthritis is dominant segment throughout forecast period. Within cell based therapy, stem cell regenerative Therapy for Osteoarthritis is most widely adopted across the globe due to its associated advantages. Hospitals end user segment of regenerative therapy for osteoarthritis is expected to be dominant in global regenerative therapies for osteoarthritis market due to high patient population EBUS procedure is generally provided on outpatient or day case basis.
Regionally, global regenerative therapies for osteoarthritis market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America regenerative therapy for osteoarthritis clearly dominates the global market due to high prevalence and growing adoption of technique by physicians and patients. Europe regenerative therapy for osteoarthritis is expected to be the second largest market regenerative medicines for osteoarthritis. Asia pacific Regenerative therapies for osteoarthritis market is expected to witness steady growth over the forecast period of 2017–2025. The Middle East & Africa regenerative therapy for osteoarthritis market accounts for a nominal value share of the overall regenerative therapies market currently, owing to the absence of adequate regulations and inability of the various governments in the region to enforce regulations, which in turn has been promoting growth of untested and illegitimate regenerative therapeutic practices in South Africa in the field of stem-cell applications.
Acelity L.P. Inc. (KCI Licensing), Acelity L.P. Inc., Mesoblast Ltd., Nuo Therapeutics, Inc. (Cytomedix), Astellas Pharma US, Inc., Organovo Holdings Inc., Orgenesis Inc., Sanofi, Athersys, Inc., Shire Pharmaceuticals Limited, and Cytori Therapeutics Inc,
MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.
The report provides the following information:
The main aim of the report is to:
MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.